ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ZYME Zymeworks Inc

6.43
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Share Name Share Symbol Market Stock Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 6.43 19:00:00
Open Price Low Price High Price Close Price Previous Close
6.43 6.43
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0 US$ 6.43 USD

Zymeworks Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
450.85M 70.12M - 76.3M -118.67M -1.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Zymeworks News

Date Time Source News Article
6/02/202318:23PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ZYME Message Board. Create One! See More Posts on ZYME Message Board See More Message Board Posts

Historical ZYME Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Zymeworks Description

Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Your Recent History

Delayed Upgrade Clock